“Mexico and other countries will want Lero. If Dr. Terán is designing the trial with only 25 patients for the severe to critical. I’m sure the results of the M2M will be more than enough proof for him.”

You bring up a valid point here: how much of an effect will positive data have on the potential trial in Mexico? The Mexico trial is only 25, compared to 50 in the U.S. I’d think Dr. Teran could take a look at the interim analysis from the severe trial and approve the drug for use in Mexico if he likes the data.